Oral Epinephrine Film Gets Allergy Meeting Debut

Adults managing severe allergies could eventually use a needle-free rescue film if the FDA approves it.

Updated on Nov. 5, 2026 in Allergies

Thin translucent amber film resting on a steel tray in a clean laboratory with soft daylight and a blurred background.
Aquestive Therapeutics will present new data on its investigational Anaphylm epinephrine film at the 2026 ACAAI meeting in Phoenix this November. AI Illustration. Upload story photo >

Aquestive Therapeutics, a biopharmaceutical company based in Warren, New Jersey, will present multiple oral and poster studies at the 2026 ACAAI Annual Meeting in Phoenix, Arizona, November 12-16, 2026. The presentations evaluate investigational Anaphylm (dibutepinephrine) sublingual film, which U.S. adults and families managing allergies may eventually encounter if it wins FDA approval.

Why it matters

Current epinephrine rescue for anaphylaxis is typically given by injection, so an orally dissolving option would change how severe allergic reactions could be treated outside the clinic. Presenting pharmacokinetic and pharmacodynamic data at a major allergy meeting lets specialists scrutinize the drug before any regulatory decision.

Aquestive will present oral and poster data at the ACAAI meeting covering dibutepinephrine pharmacokinetics in people with and without Type I allergic reaction symptoms, plus healthcare provider perspectives and pharmacodynamic effects of its sublingual epinephrine film. The results have not yet been published, so specific findings cannot be reported at this stage.

The players

Aquestive Therapeutics

A Warren, New Jersey biopharmaceutical company focused on oral drug delivery, including its AdrenaVerse epinephrine prodrug platform and the Anaphylm film candidate.

American College of Allergy, Asthma and Immunology (ACAAI)

The professional medical society whose annual meeting serves as a major forum for allergy and immunology research and clinical updates.

The details

Anaphylm is a polymer matrix-based epinephrine prodrug, meaning the active drug is delivered in a chemically modified form designed to be converted in the body. Because it is a thin sublingual film placed under the tongue, it requires no water and no swallowing, which the company positions as a potential advantage during a fast-moving allergic emergency. The presentations examine how the drug behaves in patients both with and without active allergy symptoms.

Timeline

  1. November 12, 2026: Abstracts become available online at annualmeeting.acaai.org.

  2. November 12-16, 2026: The ACAAI Annual Meeting takes place in Phoenix, Arizona.

  3. November 13, 2026, 3:05 pm MST: Karen Rance presents a poster on healthcare provider perspectives on epinephrine delivery.

  4. November 13, 2026, 3:20 pm MST: David B.K. Golden presents a poster on pharmacodynamic effects of AQST-109.

  5. November 14, 2026, 4:43 pm MST: Jay A. Lieberman gives an oral presentation on dibutepinephrine pharmacokinetics.

Health Landscape

Injectable epinephrine has been the standard first-line rescue for anaphylaxis for decades, leaving patients dependent on needles and carried devices. Oral and sublingual delivery formats are an emerging area of development aimed at making rescue treatment easier to administer.

If you or a family member carry epinephrine for allergic reactions, an oral option could one day change how rescue treatment is given, but Anaphylm is not yet approved and nothing about current treatment should change now. Anyone with a history of severe allergic reactions should keep discussing their emergency action plan with an allergist or primary care physician.

The takeaway

Oral epinephrine would be a meaningful shift if it reaches patients, since it could remove the need for injection in an emergency. Anyone managing severe allergies should review their current rescue plan with an allergist and ask about newer options as they become available.

What happens next

Abstracts go online November 12, 2026, and the poster and oral presentations are scheduled November 13-14, 2026 in Phoenix, Arizona.

Further reading

For broader context on how allergic reactions are diagnosed and managed, explore Allergies.

More information

Abstracts for the Aquestive presentations are listed on the ACAAI annual meeting abstracts site beginning November 12, 2026.

Source note: This article includes information reported by The Manila times.